Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


End-Users Should Have Greater Input In Sharps Safety Purchasing - Panel

This article was originally published in The Gray Sheet

Executive Summary

Rapid advances in sharps safety technology are making it more imperative that frontline health care workers have more input in facility decisions to purchase the devices, panelists at the Premier Sharps Safety Forum agreed April 5 in Crystal City, Virginia.

You may also be interested in...

BD Picks Up Retractable Syringe Technology Through Med-Design Deal

BD Corp. will broaden its protective sharps technology portfolio and enter the retractable sharps market in May with the introduction of Med-Design's Safety Auto-Retract Intravenous Catheter, executives from Med-Design explained during an April 5 teleconference.

Lilly’s Cyramza Wins Slim Nod, But Steba’s Tookad Falls Hard At US FDA Panel

Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts